SCHEMBL30795356

SCHEMBL30795356

COCCn1c(=O)c(C(=O)NCc2ccc(F)cc2)c(C)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
S1PR3 Q99500 2/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 3/20 0.42
HPGD P15428 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PDE10A Q9Y233 1/20 0.42
MAPT P10636 2/20 0.41
EGLN2 Q96KS0 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
EGLN3 Q9H6Z9 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28806 1.00 L3MBTL1 (0.46) L3MBTL1MEN1KMT2AS1PR3ALDH1A1
SCHEMBL30795406 0.90 S1PR3 (0.46) S1PR3ALDH1A1GAAHPGDPDE10A
SCHEMBL29501 0.90 S1PR3 (0.46) S1PR3ALDH1A1GAAHPGDPDE10A
SCHEMBL713970 0.89 L3MBTL1 (0.58) L3MBTL1MEN1KMT2AS1PR3ALDH1A1
SCHEMBL30795207 0.89 L3MBTL1 (0.58) L3MBTL1MEN1KMT2AS1PR3ALDH1A1
SCHEMBL713660 0.87 L3MBTL1 (0.47) L3MBTL1MEN1KMT2AS1PR3ALDH1A1
SCHEMBL30794933 0.87 L3MBTL1 (0.47) L3MBTL1MEN1KMT2AS1PR3ALDH1A1
SCHEMBL714808 0.87 MEN1 (0.57) L3MBTL1MEN1KMT2AALDH1A1GAA
SCHEMBL30795584 0.87 MEN1 (0.57) L3MBTL1MEN1KMT2AALDH1A1GAA
SCHEMBL29084 0.86 S1PR3 (0.43) S1PR3ALDH1A1GAAHPGDPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed